Table 8.
Diseased controls versus cases | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
Gene | Variant | RS | Studies (n) | Cases/Controls (n) | RE ORG | 95% LL | 95% UL | I2(%) | PQ | PE |
SLC2A1 | XbaI(+)>XbaI(−) | rs841853 | 9 | 1311/1226 | 1.26 | 0.98 | 1.61 | 62.31 | 0.01 | 0.04 |
SLC2A1 | All in HWE | 6 | 811/735 | 1.43 | 1.09 | 1.88 | 50.90 | 0.07 | 0.08 | |
Subgroup analyses | ||||||||||
T1DM | XbaI(+)>XbaI(−) | rs841853 | 3 | 494/443 | 1.49 | 1.00 | 2.23 | 62.13 | 0.07 | 0.16 |
T2DM | XbaI(+)>XbaI(−) | rs841853 | 6 | 817/783 | 1.14 | 0.84 | 1.57 | 60.86 | 0.03 | 0.05 |
Caucasians | XbaI(+)>XbaI(−) | rs841853 | 7 | 1121/908 | 1.19 | 0.91 | 1.56 | 62.17 | 0.01 | 0.12 |
Non-Caucasians | XbaI(+)>XbaI(−) | rs841853 | 2 | 190/318 | 1.71 | 0.69 | 4.27 | 76.70 | 0.04 | na |
Sensitivity analysis | ||||||||||
Excluding current case-control | XbaI(+)>XbaI(−) | rs841853 | 8 | 1118/1078 | 1.29 | 0.97 | 1.72 | 67.020 | 0 | 0.05 |
All in HWE | 5 | 618/587 | 1.54 | 1.09 | 2.16 | 57.70 | 0.05 | 0.13 | ||
SLC2A1 | HaeIII SNP | rs1385129 | 4 | 716/899 | 0.74 | 0.350 | 1.57 | 92.05 | 0 | 0.18 |
All in HWE | 3 | 590/749 | 1.14 | 0.73 | 1.76 | 74.96 | 0.02 | 0.11 | ||
SLC2A1 | Enh2 SNP1 G>A | rs841847 | 4 | 783/904 | 1.48 | 0.85 | 2.60 | 89.27 | 0 | 0.13 |
SLC2A1 | All in HWE | 4 | ||||||||
Subgroup analyses | ||||||||||
T1DM | Enh2 SNP1 G>A | rs841847 | 2 | 465/479 | 1.10 | 0.87 | 1.40 | 0 | 0.92 | na |
T2DM | Enh2 SNP1 G>A | rs841847 | 2 | 318/425 | 2.02 | 0.58 | 7.00 | 94.83 | 0 | na |
Caucasians | Enh2 SNP1 G>A | rs841847 | 2 | 454/382 | 1.08 | 0.85 | 1.39 | 0 | 0.96 | na |
Non-Caucasians | Enh2 SNP1 G>A | rs841847 | 2 | 329/522 | 2.06 | 0.62 | 6.86 | 94.81 | 0 | na |
Sensitivity analysis | ||||||||||
Excluding current case-control | Enh2 SNP1 G>A | rs841847 | 3 | 591/752 | 1.65 | 0.78 | 3.51 | 92.21 | 0 | 0.16 |
All in HWE | 3 | |||||||||
SLC2A1 | Enh2 SNP2 C>T | rs841848 | 3 | 588/750 | 1.18 | 0.95 | 1.45 | 0 | 0.62 | 0.35 |
All in HWE | 3 | |||||||||
Subgroup analyses | ||||||||||
T1DM | Enh2 SNP2 C>T | rs841848 | 2 | 462/477 | 1.14 | 0.88 | 1.48 | 0 | 0.37 | na |
T2DM | Enh2 SNP2 C>T | rs841848 | 1 | na | na | na | na | na | na | na |
Caucasians | Enh2 SNP2 C>T | rs841848 | 2 | 462/477 | 1.14 | 0.88 | 1.48 | 0 | 0.37 | na |
Non-Caucasians | Enh2 SNP2 C>T | rs841848 | 1 | na | na | na | na | na | na | na |
Sensitivity analysis | ||||||||||
Excluding current case-control | Enh2 SNP2 C>T | rs841848 | na | na | na | na | na | na | na | na |
SLC2A1 | HpyCH4V | rs710218 | 2 | 257/380 | 3.87 | 0.61 | 24.38 | 96.94 | 0.00 | na |
All in HWE | 2 | |||||||||
Healthy controls versus diseased controls versus cases | ||||||||||
SLC2A1 | XbaI(+)>XbaI(−) | rs841853 | 6 | 761/554/845 | 1.36 | 0.98 | 1.89 | 84.03 | 0 | 0.10 |
SLC2A1 | All in HWE | 6 | ||||||||
Subgroup analyses | ||||||||||
T1DM | XbaI(+)>XbaI(−) | rs841853 | 1 | na | na | na | na | na | na | na |
T2DM | XbaI(+)>XbaI(−) | rs841853 | 5 | 691/510/741 | 1.36 | 0.92 | 2.00 | 87.14 | 0 | 0.17 |
Caucasians | XbaI(+)>XbaI(−) | rs841853 | 5 | 697/509/721 | 1.17 | 0.91 | 1.51 | 69.98 | 0.01 | 0.21 |
Non-Caucasians | XbaI(+)>XbaI(−) | rs841853 | 1 | na | na | na | na | na | na | na |
Sensitivity analysis | ||||||||||
Excluding current case-control | XbaI(+)>XbaI(−) | rs841853 | 5 | 568/406/604 | 1.34 | 0.88 | 2.04 | 86.30 | 0 | 0.07 |
All in HWE | 5 | |||||||||
Healthy controls versus cases | ||||||||||
SLC2A1 | XbaI(+)>XbaI(−) | rs841853 | 6 | 761/845 | 1.58 | 1.01 | 2.48 | 83.03 | 0 | 0.23 |
All in HWE | 6 | |||||||||
Subgroup analyses | ||||||||||
T1DM | XbaI(+)>XbaI(−) | rs841853 | 1 | na | na | na | na | na | na | na |
T2DM | XbaI(+)>XbaI(−) | rs841853 | 5 | 691/741 | 1.56 | 0.92 | 2.65 | 86.15 | 0 | 0.28 |
Caucasians | XbaI(+)>XbaI(−) | rs841853 | 5 | 697/721 | 1.29 | 0.92 | 1.81 | 66.67 | 0.02 | 0.42 |
Non-Caucasians | XbaI(+)>XbaI(−) | rs841853 | 1 | na | na | na | na | na | na | na |
Sensitivity Analysis | XbaI(+)>XbaI(−) | rs841853 | 5 | 568/604 | 1.568 | 0.875 | 2.81 | 85.765 | 0 | 0.15 |
Excluding current case-control | All in HWE | 5 |
na: non-applicable.